MedTrace Logo

Covid-19 Infection and New Onset Type 1 Diabetes

NCT04623697 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2023-10-24

No results posted yet for this study

Summary

Although recognized as an autoimmune disease the etiology of type 1 diabetes remains unknown. Virus infections has been suggested as a possible agent triggering the autoimmune reaction finally resulting in beta-cell destruction and fate of insulin secretion. SARS Cov-2 virus enters the infected cells by binding to the ACE-2 receptor, which is abundant in many tissues including the pancreas. Accordingly, SARS Covid-19 infection may trigger the development of type 1 diabetes either by an activation of the immune system or directly via beta-cell infection and destruction.

Our aim is to study the impact of the Covid-19 epidemic on the development of type 1 diabetes. This will be done in two ways: a clinical study and an epidemiological follow up. During the next two years, adult patients with newly diagnosed type 1 diabetes will be asked to participate. Type 1 diabetes will be diagnosed by usual means and a mixed meal tolerance test will be performed at time of diagnosis and after one year to evaluate beta-cell function. People with type 1 diabetes and serologically documented previous SARS Covid-19 will be compared with people with no previous infection regarding beta-cell function and fate of insulin secretion. In addition, we will estimate the number of new diagnosed type 1 diabetes patients compared to previous years.

Conditions

  • Covid19
  • type1diabetes

Sponsors & Collaborators

  • Steno Diabetes Center Odense

    collaborator OTHER

  • Steno Diabetes Center Nordjylland

    collaborator OTHER

  • Aarhus University Hospital

    collaborator OTHER

  • Steno Diabetes Center Sjaelland

    collaborator OTHER_GOV

  • Steno Diabetes Center Copenhagen

    collaborator OTHER

  • Esbjerg Hospital - University Hospital of Southern Denmark

    lead OTHER

Principal Investigators

  • Claus B Juhl · Esbjerg Hospital - University Hospital of Southern Denmark

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04623697 on ClinicalTrials.gov